Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Silver

Showing results (191-200 of 232) with videos related to

Pageof 24
Sort By:
The Cancer Journal From Scientific American|November 1, 1995
Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapyD H Henry, B J Brooks, D C Case, et al.
Blood Cancer Journal|March 9, 2013
Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH SymposiumA Tefferi, O Abdel-Wahab, F Cervantes, et al.
Hemasphere|May 10, 2021
Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 TrialClaire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|October 8, 2019
Incremental Utility of Right Ventricular Dysfunction in Patients With Myeloproliferative Neoplasm-Associated Pulmonary HypertensionJiwon Kim, Spencer Krichevsky, Lola Xie, et al.
Blood|August 30, 2002
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemiasOliver G Ottmann, Brian J Druker, Charles L Sawyers, et al.
Blood|December 2, 2006
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapyAndreas Hochhaus, Hagop M Kantarjian, Michele Baccarani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2011
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNetTiziano Barbui, Giovanni Barosi, Gunnar Birgegard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2013
Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trialRuben A Mesa, Jason Gotlib, Vikas Gupta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 1998
Comparison of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors. Cancer and Leukemia Group BA B Kornblith, J E Herndon, E Zuckerman, et al.
Journal of the National Cancer Institute|September 7, 2021
Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase InhibitorsKelly L Schoenbeck, Ehab Atallah, Li Lin, et al.
Pageof 24

Showing results (191-200 of 232) with videos related to

Sort By:
Pageof 24
The Cancer Journal From Scientific American|November 1, 1995
Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapyD H Henry, B J Brooks, D C Case, et al.
Blood Cancer Journal|March 9, 2013
Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH SymposiumA Tefferi, O Abdel-Wahab, F Cervantes, et al.
Hemasphere|May 10, 2021
Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 TrialClaire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|October 8, 2019
Incremental Utility of Right Ventricular Dysfunction in Patients With Myeloproliferative Neoplasm-Associated Pulmonary HypertensionJiwon Kim, Spencer Krichevsky, Lola Xie, et al.
Blood|August 30, 2002
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemiasOliver G Ottmann, Brian J Druker, Charles L Sawyers, et al.
Blood|December 2, 2006
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapyAndreas Hochhaus, Hagop M Kantarjian, Michele Baccarani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2011
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNetTiziano Barbui, Giovanni Barosi, Gunnar Birgegard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2013
Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trialRuben A Mesa, Jason Gotlib, Vikas Gupta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 1998
Comparison of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors. Cancer and Leukemia Group BA B Kornblith, J E Herndon, E Zuckerman, et al.
Journal of the National Cancer Institute|September 7, 2021
Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase InhibitorsKelly L Schoenbeck, Ehab Atallah, Li Lin, et al.
Pageof 24